Cabaletta Bio, Inc. (CABA)
NASDAQ: CABA · Real-Time Price · USD
2.860
-0.050 (-1.72%)
At close: Apr 28, 2026, 4:00 PM EDT
2.878
+0.018 (0.63%)
After-hours: Apr 28, 2026, 4:46 PM EDT
Cabaletta Bio Stock Forecast
Stock Price Forecast
The 6 analysts with 12-month price forecasts for Cabaletta Bio stock have an average target of 14.5, with a low estimate of 2.00 and a high estimate of 30. The average target predicts an increase of 406.99% from the current stock price of 2.86.
Analyst Consensus: Strong Buy
* Price targets were last updated on Mar 24, 2026.
Analyst Ratings
The average analyst rating for Cabaletta Bio stock from 6 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 4 | 3 |
| Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Hold | 2 | 2 | 2 | 2 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 8 | 8 | 8 | 7 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Morgan Stanley | Morgan Stanley | Buy Maintains $14 → $13 | Buy | Maintains | $14 → $13 | +354.55% | Mar 24, 2026 |
| Guggenheim | Guggenheim | Strong Buy Maintains $15 → $16 | Strong Buy | Maintains | $15 → $16 | +459.44% | Mar 24, 2026 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Maintains $15 → $30 | Buy | Maintains | $15 → $30 | +948.95% | Oct 31, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $16 | Strong Buy | Reiterates | $16 | +459.44% | Oct 10, 2025 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates $15 | Buy | Reiterates | $15 | +424.48% | Sep 5, 2025 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
1.95M
EPS This Year
-1.60
from -2.10
EPS Next Year
-1.55
from -1.60
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | n/a | 14.1M | ||||||
| Avg | n/a | 2.0M | ||||||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 |
|---|---|---|---|---|---|---|---|
| High | -1.05 | -0.88 | |||||
| Avg | -1.60 | -1.55 | |||||
| Low | -2.09 | -2.58 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 |
|---|---|---|---|---|---|---|---|
| High | - | - | |||||
| Avg | - | - | |||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.